Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FTC files for injunction against hoodia marketer

This article was originally published in The Tan Sheet

Executive Summary

The Federal Trade Commission files a permanent injunction against supplement firms Stella Labs and Nutraceuticals International, along with certain officers of the firms, for deceptive marketing of products containing hoodia. FTC sought the injunction due to Paramus, N.J.-based Stella Labs and Nutraceuticals International Elmwood Park, N.J.-based Nutraceuticals International allegedly "engaging in deceptive acts or practices and false advertising in connection with the advertising, marketing, and sale of a purported weight-loss product," according to the complaint filed March 30 in the U.S. District Court of New Jersey

You may also be interested in...



France Rejects Advice To Delay Second Dose Of Pfizer Vaccine

The French government has decided not to extend the recommended interval between the two doses of the Pfizer/BioNTech coronavirus vaccine. 

Biosimilars Boost Offsets Generics Slide For Sandoz

Despite the turbulence of 2020 and the pressures of the coronavirus pandemic, Sandoz has reported steady sales for the year, as biopharmaceuticals sales up by a fifth offset a slide in turnover from retail generics.

Speculation Over Moderna Vaccine Deal With Tata, Wockhardt

Moderna is speculated to be in talks with Indian firms, including Wockhardt and a Tata group company, for manufacturing its COVID-19 vaccine. A deal in India could help the company meet its obligation to supply COVAX but Moderna is likely to choose its partner carefully.

Topics

UsernamePublicRestriction

Register

OM004634

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel